Altered Gene Expression Pattern in Peripheral Blood Mononuclear Cells in Patients with Acute Myocardial Infarction

Marek Kiliszek1*, Beata Burzynska2*, Marcin Michalak1, Monika Gora2, Aleksandra Winkler1, Agata Maciejak2, Agata Leszczynska2, Ewa Gajda1, Janusz Kochanowski1, Grzegorz Opolski1

1 First Chair and Department of Cardiology, Medical University of Warsaw, Warsaw, Poland, 2 Institute of Biochemistry and Biophysics, Polish Academy of Sciences, Warsaw, Poland

Abstract

**Background:** Despite a substantial progress in diagnosis and therapy, acute myocardial infarction (MI) is a major cause of mortality in the general population. A novel insight into the pathophysiology of myocardial infarction obtained by studying gene expression should help to discover novel biomarkers of MI and to suggest novel strategies of therapy. The aim of our study was to establish gene expression patterns in leukocytes from acute myocardial infarction patients.

**Methods and Results:** Twenty-eight patients with ST-segment elevation myocardial infarction (STEMI) were included. The blood was collected on the 1st day of myocardial infarction, after 4–6 days, and after 6 months. Control group comprised 14 patients with stable coronary artery disease, without history of myocardial infarction. Gene expression analysis was performed with Affymetrix Human Gene 1.0 ST microarrays and GCS3000 TG system. Lists of genes showing altered expression levels (fold change >1.5, p<0.05) were submitted to Ingenuity Pathway Analysis. Gene lists from each group were examined for canonical pathways and molecular and cellular functions. Comparing acute phase of MI with the same patients after 6 months (stable phase) and with control group we found 24 genes with changed expression. In canonical analysis three pathways were highlighted: signaling of PPAR (peroxisome proliferator-activated receptor), IL-10 and IL-6 (interleukin 10 and 6).

**Conclusions:** In the acute phase of STEMI, dozens of genes from several pathways linked with lipid/glucose metabolism, platelet function and atherosclerotic plaque stability show altered expression. Up-regulation of SOCS3 and FAM20 genes in the first days of myocardial infarction is observed in the vast majority of patients.

**Citation:** Kiliszek M, Burzynska B, Michalak M, Gora M, Winkler A, et al. (2012) Altered Gene Expression Pattern in Peripheral Blood Mononuclear Cells in Patients with Acute Myocardial Infarction. PLoS ONE 7(11): e50054. doi:10.1371/journal.pone.0050054

**Editor:** Rakesh Kukreja, Virginia Commonwealth University Medical Center, United States of America

**Received** March 27, 2012; **Accepted** October 15, 2012; **Published** November 21, 2012

**Copyright:** © 2012 Kiliszek et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

**Funding:** This work was supported by grant R13 0001 06 from The National Centre for Research and Development (NCBiR). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

**Competing Interests:** The authors have declared that no competing interests exist.

* E-mail: kiliszek@mp.pl (MK); atka@ibb.waw.pl (BB)

Introduction

Acute myocardial infarction (MI) remains the leading cause of death despite the substantial progress in diagnosis and therapy in recent decades. In the acute phase of MI increased leukocyte count, a non-specific marker of inflammation, is the risk factor for future cardiovascular events and predicts mortality in those with STEMI [ST-segment elevation MI], NSTEMI [non-STEMI] or unstable angina [1,2]. It has also been shown that an elevated leukocyte count predicts 1-year mortality independently of the risk factors for coronary artery disease across the entire spectrum of acute coronary syndromes (ACS) [3]. The mechanisms linking activation of inflammation and ACS are complex – inflammation seems to be linked to the initiation and progression of atherosclerosis [4]. Obtaining novel insights into the pathophysiology of myocardial infarction by analyzing gene expression patterns in leukocytes should aid the discovery of novel biomarkers of MI and elaboration of novel therapeutic strategies. The aim of our pilot study was the first attempt at establishing leukocyte gene expression signatures of the acute phase of MI.

**Materials and Methods**

**Patients**

Patients presenting with STEMI were included in the Ist Chair and Department of Cardiology of Medical University of Warsaw in 2010. We sought to include consecutive patients that agreed to participate in the study (due to technical aspects of blood collection, only patients admitted between Sunday and Thursday were taken into consideration). All the patients underwent coronary angiography and angioplasty of infarct related artery. Pharmacological treatment was according to current guidelines [5]. Blood was collected on the 1st day of myocardial infarction (admission), after 4–6 days (discharge), and after 6 months. Participation in the study had no influence on the pharmacological treatment and procedures underwent by the patients. Control
group comprised patients with proven coronary artery disease: with coronary angiography (at least one stenosis exceeding 50% or previous coronary angioplasty of previous coronary artery bypass graft), or with non-invasive tests (positive exercise test) and no history of myocardial infarction. The study was approved by the Bioethics Committee of the Medical University of Warsaw and all patients gave written informed consent.

**RNA Isolation**

Sodium-heparinized blood was collected from 28 patients at the three time points. Peripheral blood mononuclear cells (PBMC) were purified using BD Vacutainer® CPT™ Cell Preparation Tube according to the manufacturer’s instructions (Becton, Dickinson and Co. Franklin Lakes, NJ, USA).

Total RNA was isolated from PBMC with the MagNA Pure Compact System (Roche Diagnostics GmbH, Germany) according to the manufacturer’s recommendations. RNA samples were quantified by UV absorption [Nanodrop, LabTech International, UK] and their quality was checked with the RNA 600 Nano Assay Kit using Bioanalyzer® according to the manufacturer’s procedures (Agilent, Santa Clara, CA, USA). Samples with an RNA integrity number of eight or above were considered suitable for use in microarrays. RNA samples were stored at −80°C until further analysis.

**cDNA Microarrays**

RNA (100 ng) was reverse transcribed, amplified, and labeled with biotin using the whole transcript sense target labeling kit and hybridized for 16 h at 45°C to Human Gene 1.0 ST arrays (Affymetrix, Santa Clara, CA, USA), according to the manufacturer’s instructions. Following hybridization, the probe arrays were washed and stained on a fluidics station and immediately scanned on an Affymetrix GCS 3000 GeneArray Scanner.

**Data Analysis of Microarrays**

Quality controls were performed using Microarray Suite 5.0 software provided by Affymetrix (www.affymetrix.com) according to the manufacturer’s recommendations. Affymetrix raw gene array data were processed using the Partek Genomics Suite software (Partek Inc., St. Louis, MO, USA).

Comparisons were performed between MI group at day one of day 4–6 on the one hand and MI group at 6 months or control on the other. Lists of genes showing significant differences in expression levels between groups were submitted to Ingenuity Pathway Analysis (Ingenuity® Systems, www.ingenuity.com) for canonical pathways and subjected to network analyses.

**Determination of mRNA Levels by qRTPCR**

Total RNA was converted into cDNA using the QuantiTect Reverse Transcription Kit (Qiagen, Germany) according to the manufacturer’s recommendations.

qPCR amplification was performed using a using LightCycler 1.5 and LightCycler 480 Instruments, and LightCycler FastStart DNA Master SYBR Green I and LightCycler 480 SYBR Green I Master (Roche Diagnostics GmbH, Germany) according to the manufacturer’s instructions. The Pfaffl model [6] and the relative expression software tool (REST-MCS®-version 2) [7] were used to estimate changes in the relative mRNA levels of a 24 genes in order to validate the results obtained in the microarray study. We determined the relative expression levels of the selected genes at the 1st day of myocardial infarction (on admission), 6 months after MI and in the control group, using samples from six randomly chosen patients from both groups. Data normalization was carried out against transcripts of the HPRT and TUBB genes. The sequences of all primers and qPCR amplification parameters are available in supplementary data (Table S1).

**Statistical analysis.** Continuous variables are presented as mean ±SD (standard deviation). Categorical variables are presented as frequencies. Statistical significance of the results was estimated by variance analysis (ANOVA). Differences were considered statistically significant at a nominal significance of p<0.05 and a fold change >1.5 in expression between the admission, discharge and control groups.

**Results**

Twenty-eight patients with ST-segment elevation myocardial infarction (STEMI) were included. All the patients completed the follow-up visit 6 months after admission. The control group comprised 14 patients. Basic characteristics of the groups are shown in Table 1.

**Admission**

On the first day of MI 91 genes showed a significantly different level of expression compared with 6 months after MI. Of those, 57 were annotated, including three pairs of duplicate genes. Of the 54 unique annotated genes with altered expression 51 were up- and three down-regulated at day 1 versus 6 months (Table S2). In turn, a comparison of gene expression on the first day of MI with the control group identified 491 genes a significantly differentially expressed (212 annotated, including 14 pairs of duplicate genes, 85 were up- and 127 down-regulated, Table S3). Twenty-four genes were shared between the two comparisons (MI vs. after 6 months and MI vs. control, Table 2).

**Table 1. Major characteristics of the study and control groups.**

| Treatment                  | Study group | Control group | p-value |
|----------------------------|-------------|---------------|---------|
| Aspirin**                  | 28 (100%)   | 12 (85.7%)    | 0.20    |
| Clopidogrel**              | 28 (100%)   | 3 (21.4%)     | <0.0001 |
| Statin**                   | 28 (100%)   | 13 (92.8)     | 0.72    |
| Beta blocker**             | 28 (100%)   | 13 (92.8)     | 0.72    |
| ACE inhibitor**            | 20 (71.4%)  | 12 (85.7%)    | 0.52    |
| Heparin (UFH or LMWH)**    | 28 (100%)   | 0 (0%)        | <0.0001 |

*Mean ± Standard Deviation.
**number (%);
NA – not applicable.
doi:10.1371/journal.pone.0050054.t001
In a canonical analysis of the genes with altered expression several pathways were found, the most significant being: signaling of PPAR (peroxisomal proliferator-activated receptor), IL-6 (interleukin 6) signaling, and IL-10 (interleukin 10) signaling. These pathways were common for both comparisons (Figure 1).

Additionally, a comparison between day one and after 6 months revealed significant changes in glucocorticoid receptor signaling and activation of LXR/RXR (liver × receptor/retinoid × receptor). In contrast, analysis of the day one MI group versus the control highlighted genes associated with Complement System, Coagulation System, Natural Killer Cell Signaling, and Extrinsic Prothrombin Activation Pathway.

In the molecular and cellular function categories Cellular Growth and Proliferation, Cell-To-Cell Signaling and Interaction, and Cell Movement were markedly changed in both analyses.

To validate the microarray results, mRNA levels of twenty-four genes shared between the two comparisons were quantified by qRT-PCR (Table 3). Results of validation confirmed the microarray data and for most of the genes the fold-changes calculated by qRT-PCR exceeded the microarray ones.

Discharge

On the 4th–6th day after MI expression of 34 genes was changed relative to 6 months after MI: 18 with annotation including two pairs and one gene represented by seven probes, which makes 10 unique genes, all upregulated (Table S4). In a canonical analysis five most significant pathways were: Primary Immunodeficiency Signaling, B Cell Development; Communication between Innate and Adaptive Immune Cells; Systemic Lupus Erythematosus Signaling; Role of Macrophages, Fibroblasts and Endothelial Cells in Rheumatoid Arthritis.

Analysis of 4th–6th day after MI versus the control group indicated 302 differentially expressed genes with 98 of them annotated, including three pairs of duplicates; 26 up- and 72 down-regulated (Table S5). Association with Hematopoiesis from Pluripotent Stem Cells, Primary Immunodeficiency Signaling, Natural Killer Cell Signaling, Complement System, and EIF2 Signaling canonical pathways was found.

Genes Shared between Admission and Discharge

Taking into account genes common to the two analyses of gene expression on admission and on discharge versus after 6 months, Table 2.

| Admission vs 6 months | Admission vs control |
|-----------------------|----------------------|
| **Fold Change** | **p-value** | **Fold Change** | **p-value** | **Symbol** | Entrez Gene Name |
| 1.505 | 1.36E−09 | 1.664 | 7.16E−07 | MYBL1 | v-myb myeloblastosis viral oncogene homolog (avian)-like 1 |
| 1.563 | 1.51E−07 | 2.006 | 2.14E−05 | KLRC4 | killer cell lectin-like receptor subfamily C, member 4 |
| 1.578 | 2.30E−06 | 2.213 | 6.33E−05 | KLRC2 | killer cell lectin-like receptor subfamily C, member 2 |
| 1.518 | 5.04E−13 | 2.236 | 1.07E−02 | TMEM176A | transmembrane protein 176A |
| 1.570 | 1.68E−16 | 1.753 | 2.51E−08 | ST14, MT-SP1/matriptase | suppression of tumorigenicity 14 (colon carcinoma) |
| 1.573 | 5.36E−05 | 1.732 | 1.74E−04 | HBEGF | heparin-binding EGF-like growth factor |
| 1.577 | 5.82E−16 | 1.950 | 1.62E−09 | ASGR2 | asialoglycoprotein receptor 2 |
| 1.584 | 5.95E−14 | 1.989 | 3.39E−10 | STAB1 | stabilin 1 |
| 1.587 | 3.26E−03 | 1.605 | 2.50E−02 | EGR2 | early growth response 2 |
| 1.589 | 1.07E−06 | 1.555 | 1.48E−03 | FMN1 (includes EG:296512) | formin 1 |
| 1.601 | 6.36E−12 | 1.533 | 2.03E−04 | CR1 | complement component (3b/4b) receptor 1 (Knops blood group) |
| 1.611 | 3.11E−13 | 1.674 | 2.68E−05 | RNASE1 | ribonuclease, RNase A family, 1 (pancreatic) |
| 1.629 | 1.88E−12 | 1.837 | 1.40E−06 | TCN2 | transcobalamin II |
| 1.638 | 4.61E−11 | 1.512 | 1.62E−04 | V5G4 | V-set and immunoglobulin domain containing 4 |
| 1.669 | 6.74E−12 | 1.586 | 3.42E−05 | CYP1B1 | cytochrome P450, family 1, subfamily B, polypeptide 1 |
| 1.693 | 6.24E−13 | 1.771 | 3.90E−05 | DYSF | dysferlin, limb girdle muscular dystrophy 2B (autosomal recessive) |
| 1.761 | 1.99E−11 | 1.769 | 1.33E−04 | RNASE2 | ribonuclease, RNase A family, 2 (liver, eosinophil-derived neurotoxin) |
| 1.778 | 9.45E−13 | 1.711 | 1.84E−07 | PPARG | peroxisome proliferator-activated receptor gamma |
| 1.904 | 9.39E−11 | 1.631 | 1.25E−03 | FCGR1A | Fc fragment of IgG, high affinity Ia, receptor (CD64) |
| 1.945 | 1.01E−10 | 1.972 | 2.16E−05 | FAM20A | family with sequence similarity 20, member A |
| 1.958 | 1.71E−15 | 1.732 | 4.98E−05 | AQP9 | aquaporin 9 |
| 2.066 | 5.51E−05 | 1.955 | 4.17E−03 | EGR1 | early growth response 1 |
| 2.339 | 9.00E−14 | 2.008 | 4.14E−04 | HP | haptoglobin |
| 2.929 | 1.60E−20 | 2.443 | 5.10E−09 | SOCS3 | suppressor of cytokine signaling 3 |

doi:10.1371/journal.pone.0050054.t002
only two transcripts showed significantly altered expression: FAM20A and SOCS3. In contrast, when the same admission and discharge groups were compared with the control 75 genes were shared between the two comparisons, including 39 down-regulated small non-coding RNA transcripts (Table 4).

Additionally, we undertook a patient-by-patient analysis of the most differently expressed genes between all groups. The direction of change was the same in all patients although the relative levels of expression differed markedly between patients (Figure 2).

**Discussion**

We have shown here that in leukocytes of STEMI patients tens of genes show altered expression during or soon after MI relative to the stable coronary artery disease. Interestingly, at the day of the infarct they include mainly genes and pathways directly or indirectly linked with lipid/glucose metabolism, platelet function and atherosclerotic plaque stability. On discharge, many genes related to specific immune response (encoding immunoglobulins) show altered expression. Comparing the admission and the...
Table 3. Validation of microarray data using qRT-PCR.

| Gene Symbol | Admission vs 6 months | Admission vs control |
|-------------|-----------------------|----------------------|
| KLRC2       | 0.59 (0.43)           | 0.22 (0.13)          |
| MYBL1       | 0.55 (0.19)           | 0.56 (0.20)          |
| KLRC4       | 0.51 (0.34)           | 0.65 (0.41)          |
| SOCS3       | 12.63 (5.23)          | 5.42 (2.21)          |
| FM20A       | 6.31 (3.09)           | 3.56 (1.62)          |
| EGR1        | 5.82 (4.54)           | 6.64 (5.85)          |
| PPARG       | 4.20 (1.71)           | 4.28 (1.76)          |
| HP          | 4.00 (2.75)           | 3.12 (1.88)          |
| HBG1        | 3.79 (2.05)           | 2.77 (1.53)          |
| EGR2        | 3.68 (3.26)           | 6.93 (6.60)          |
| VSG4        | 3.62 (1.42)           | 3.72 (1.53)          |
| AQP9        | 3.28 (1.34)           | 2.44 (0.87)          |
| STAB1       | 2.97 (1.08)           | 1.64 (0.45)          |
| ST14        | 2.79 (0.81)           | 1.61 (0.45)          |
| RNASE2      | 2.79 (1.06)           | 2.08 (0.76)          |
| CR1         | 2.67 (0.83)           | 2.88 (1.01)          |
| RNASE1      | 2.67 (0.91)           | 3.07 (1.16)          |
| CYP1B1      | 2.65 (0.77)           | 1.78 (0.57)          |
| FCGR1A      | 2.65 (1.07)           | 1.92 (0.68)          |
| ASGR2       | 2.49 (0.92)           | 2.45 (0.83)          |
| DYSF        | 2.48 (1.05)           | 1.60 (0.58)          |
| TCN2        | 2.05 (0.57)           | 1.57 (0.42)          |
| TMEM176A    | 2.00 (0.98)           | 8.77 (5.20)          |
| FMN1        | 1.72 (0.63)           | 3.64 (1.82)          |

***p<0.001; **p<0.01; *p<0.05; NS – not significant.
All genes abbreviations are explained in Table 2.
doi:10.1371/journal.pone.0050054.0003

Gene Expression

Below we discuss selected literature references indicating a possible relevance of individual genes showing altered expression in this study (see Table 2) to the functioning of the cardiovascular system.

We have shown up-regulation of SOCS3 and FM20 genes in the first 4–6 days of myocardial infarction. SOCS3 is one of the eight proteins of the SOCS group that block the JAK [Janus kinase] tyrosine kinase activity and the activation of STAT factors [9]. Expression of SOCS3 has been shown to be significantly reduced in balloon-injured porcine coronary arteries [10]. Recently it was reported that the progression of LV remodeling after AMI was prevented in SOCS3-deficient mice. SOCS3 deletion enhanced multiple cardioprotective signaling pathways including STAT3, AKT, and extracellular signal-regulated kinase (ERK)-1/2, while inhibiting myocardial apoptosis and fibrosis [11].

The FM20 family comprises secreted proteins with potential roles in regulating differentiation and functioning of hematopoietic and other tissues. The FM20A mRNA is only expressed during early stages of hematopoietic development [12]. The role of FM198B is unknown.

ST14 (MT-SPI/matriptase) of plays roles in growth factor activation, receptor activation and inactivation, protease activation, and ectodomain shedding [13]. In atherosclerotic lesions, enhanced mRNA and protein expression of ST14 was found relative to nondiseased vessels [14]. Asialoglycoprotein receptor (ASGPR) is a hepatic lectin responsible for selective binding and internalization of galactose/N-acetylgalactosamine-terminating glycoproteins by hepatic parenchymal cells [15]. ASGPR plays a role in regulating platelet life span and activation [16], which suggest a potential link of ASGR with coronary disease and acute coronary syndromes. The aquaporin (AQP) family members are fundamental in transmembrane water movements [17]. The specific function of AQP9 is to maximize glycerol influx and urea efflux during gluconeogenesis, as this channel is more permeable to glycerol and urea than to water [18]. Using an AQP9-knockout mice model it has been shown that AQP9 is important for hepatic glycerol metabolism and may play a role in glycerol and glucose metabolism in diabetes mellitus [19].

Early growth response-1 (EGR1) plays a role in the pathogenesis of atherosclerotic lesions, intimal thickening after acute vascular injury, ischemic pathology, angiogenesis, allograft rejection, and cardiac hypertrophy. Additionally, EGR-1 regulates expression of molecules critically linked with atherogenesis and lesion progression [20, 21, 22]. Peroxisome proliferator-activated receptor G (PPARG), a member of the PPAR subfamily of nuclear hormone receptors, has a key role in adipogenesis, insulin sensitivity, and glucose and lipid metabolism, and also plays a major role in vascular biology, modulating atherosclerosis progression and vascular endothelial function [23, 24]. Killer cell lectin-like receptor subfamily C, member 2 (KLRC2) and member 4 (KLRC4) are expressed primarily in natural killer (NK) cells and are a family of transmembrane proteins characterized by a type II membrane orientation and the presence of a C-type lectin domain. NK cells are an important component of the innate immune system through target cell killing and cytokine production. A direct evidence for NK cell involvement in atherogenesis is scant, although some researchers have localized NK cells to the human atherosclerotic plaque [25, 26]. RNASE2–RNase A family, 2 (liver, eosinophil-derived neurotoxin) is a distinct cationic protein of the eosinophil’s large specific granule known primarily for its ability to induce ataxia, paralysis, and central nervous system cellular degeneration [27]. FCGR1A – Fc fragment of IgG, high affinity 1A, receptor (CD64) is unique within the FCGR family which mediates important immune defense functions by inducing cell surface changes on human leukocytes [28, 29]. Activating FCGRs can induce phagocytosis, antigen presentation, the production of reactive oxygen species (ROS) and cytokines [29].

Canonical Analysis

Activation of PPAR changes gene transcription to modulate several clinically important metabolic functions; it improves the lipid profile and corrects hyperglycaemia and insulin resistance [30]. Interestingly, PPAR and retinoid χ receptor (RXR) cooperate in metabolic regulation. Numerous PPAR agonists are used in clinical setting (fibates) or are currently under investigation for therapeutic application (thiazolidinediones).
Table 4. Differentially expressed genes common to both analyses: admission versus control and discharge versus control.

| Admission vs control | Discharge vs control |
|----------------------|----------------------|
| Fold Change          | p-value              | Fold Change          | p-value              | Symbol                  | Entrez Gene Name                                      |
| 2.308                | 1.07E–11             | 2.306                | 1.960                | SNORD105               | small nucleolar RNA, C/D box 105                       |
| 2.301                | 5.66E–12             | 2.065                | 6.93E–08             | SNORD60                | small nucleolar RNA, C/D box 60                        |
| 2.293                | 2.24E–16             | 2.026                | 3.11E–13             | SCARNA6                | small Cajal body-specific RNA 6                        |
| 2.256                | 6.24E–15             | 2.095                | 3.85E–13             | RPL13A                 | ribosomal protein L13a                                |
| 2.227                | 1.22E–10             | 2.062                | 3.14E–09             | RABGGTB                | Rab geranylgeranyltransferase, beta subunit            |
| 2.213                | 6.33E–05             | 1.938                | 7.42E–04             | KLRC2                  | killer cell lectin-like receptor subfamily C, member 2 |
| 2.110                | 4.52E–06             | 1.615                | 2.36E–03             | MS4A3                  | membrane-spanning 4-domains, subfamily A, member 3 (hematopoietic cell-specific) |
| 2.108                | 1.48E–07             | 2.005                | 7.56E–07             | SNORDB2                | small nucleolar RNA, C/D box 82                        |
| 2.102                | 4.49E–09             | 1.960                | 6.93E–08             | SNORD50A               | small nucleolar RNA, C/D box 50A                       |
| 2.081                | 3.30E–18             | 1.964                | 2.12E–16             | SNORD50A               | small nucleolar RNA, C/D box 50A                       |
| 2.063                | 6.32E–08             | 1.904                | 1.04E–06             | SNORD61                | small nucleolar RNA, C/D box 61                        |
| 2.057                | 5.83E–09             | 1.966                | 3.53E–08             | SNHG3                  | small nucleolar RNA host gene 3 (non-protein coding)   |
| 2.053                | 8.31E–20             | 2.034                | 1.67E–19             | SNORD15B               | small nucleolar RNA, C/D box 15B                       |
| 2.047                | 1.29E–10             | 1.949                | 1.30E–09             | SNORD41                | small nucleolar RNA, C/D box 41                        |
| 2.044                | 3.75E–18             | 1.863                | 3.49E–15             | SCARNA7                | small Cajal body-specific RNA 7                        |
| 2.012                | 5.22E–06             | 1.934                | 1.55E–05             | RNU4-2                 | RNA, U4 small nuclear 2                               |
| 2.006                | 2.14E–05             | 1.708                | 8.59E–04             | KLRC4                  | killer cell lectin-like receptor subfamily C, member 4 |
| 1.994                | 6.60E–12             | 1.906                | 7.73E–11             | SCARNA10               | small Cajal body-specific RNA 10                       |
| 1.983                | 1.77E–10             | 1.833                | 8.01E–09             | SNORD1C                | small nucleolar RNA, C/D box 1C                        |
| 1.982                | 1.44E–04             | 1.709                | 2.52E–03             | KLRC3                  | killer cell lectin-like receptor subfamily C, member 3 |
| 1.972                | 7.41E–15             | 1.848                | 5.48E–13             | SNORA68                | small nucleolar RNA, H/ACA box 68                      |
| 1.946                | 2.00E–12             | 1.833                | 6.50E–11             | SNORD54                | small nucleolar RNA, C/D box 54                        |
| 1.944                | 4.72E–15             | 1.915                | 1.33E–14             | LLPH                   | LLP homolog, long-term synaptic facilitation (Aplysia) |
| 1.824                | 2.81E–12             | 1.721                | 1.16E–10             | RMRP                   | RNA component of mitochondrial RNA processing endoribonuclease |
| 1.784                | 1.75E–10             | 1.672                | 7.20E–09             | SCARNA5                | small Cajal body-specific RNA 5                        |
| 1.770                | 2.35E–10             | 1.705                | 2.07E–09             | SNHG10                 | small nucleolar RNA host gene 10 (non-protein coding)  |
| 1.755                | 3.86E–10             | 1.602                | 6.87E–08             | SNORA3                 | small nucleolar RNA, H/ACA box 3                       |
| 1.747                | 6.99E–08             | 1.613                | 2.46E–06             | SNORA23                | small nucleolar RNA, H/ACA box 23                      |
| 1.744                | 6.49E–09             | 1.517                | 6.28E–06             | CEP78                  | centrosomal protein 78Da                              |
| 1.727                | 3.33E–05             | 1.505                | 1.54E–03             | KLRC1                  | killer cell lectin-like receptor subfamily C, member 1 |
| 1.726                | 7.94E–09             | 1.507                | 6.80E–06             | SNORD28                | small nucleolar RNA, C/D box 28                        |
| 1.725                | 1.43E–10             | 1.647                | 2.52E–09             | HIST1H4A (includes others) | histone cluster 1, H4a                              |
| 1.725                | 5.62E–05             | 1.506                | 2.07E–03             | SNORD104               | small nucleolar RNA, C/D box 104                       |
| 1.718                | 5.48E–05             | 1.521                | 1.47E–03             | DTHD1                  | death domain containing 1                             |
| 1.717                | 5.51E–07             | 1.544                | 3.82E–05             | SNHG1                  | small nucleolar RNA host gene 1 (non-protein coding)   |
| 1.716                | 1.83E–16             | 1.674                | 1.67E–15             | SNORA37                | small nucleolar RNA, H/ACA box 37                      |
| 1.694                | 2.56E–07             | 1.635                | 1.27E–06             | SNORD58A               | small nucleolar RNA, C/D box 58A                       |
| 1.693                | 6.32E–08             | 1.677                | 1.01E–07             | RNUSA-1                | RNA, USA small nuclear 1                               |
| 1.689                | 1.23E–10             | 1.585                | 7.26E–09             | SNORD46                | small nucleolar RNA, C/D box 46                        |
IL-6 seems to have proatherogenic effects. Its serum concentration is elevated in acute myocardial infarction [31] and predicts events in the follow-up [32]. IL-6 has been shown to enhance fatty lesion development in mice [33]. IL-6 signaling is regulated by a family of endogenous JAK kinase inhibitor proteins, suppressors of cytokine signaling (SOCS) [34]. SOCS3 has a differential effect on IL-6 and IL-10 receptor signaling: the IL-6 receptor signaling is down-regulated by SOCS3, whereas that by IL-10 receptor is not [35]. In mice, leukocyte-derived IL-10 prevents the development of advanced atherosclerosis and plays a critical role in the modulation of the cellular and collagen plaque composition [36]. On the other hand, an elevated baseline plasma level of IL-10 has been reported as a strong and independent predictor of long-term adverse cardiovascular outcome in patients with acute coronary syndrome [37].

LXR/RXR plays important roles in cholesterol metabolism and regulates a number of immune and inflammatory pathways that have the potential to modulate development of atherosclerotic lesion [38].

### Study Limitations

Since no data on gene expression in STEMI has been published so far (means, standard deviations, etc.), we conducted a pilot study with a rather small number of patients. The results should be confirmed on a larger and independent cohort. Our group was homogenous (STEMI patients only, with angioplasty of infarct-related artery) and well-characterized clinically. We compared expression with two controls: the same group after six months (this approach has several strengths: age, sex and risk factors are the same, and the STEMI phase can be compared with the subsequent stable phase of the coronary artery disease) and an independent control group with coronary artery disease, but without myocardial infarction. Our aim was to find genes showing changed expression specifically during MI, but not those associated with stable coronary artery disease (that is why we did not take healthy controls). Thanks to such choice also the treatment of both groups was comparable, with the exception of a clopidogrel and – obviously – heparin. Our control group was older than the experimental group, but when we compared age 1st
Figure 2. Expression data from microarray experiments for chosen genes. The y-axis represents the log2 normalized intensity of the gene and the x-axis represents analyzed groups. The line inside the box and whiskers represents the median of the samples in a group. Points present relative expression levels in individual patients at admission (blue), at discharge (green), 6 month after MI (violet) and from control group (red). Numbers indicate the coded identity of a particular patient. SOCS3—suppressor of cytokine signaling 3; ST14—MT-SP1/matriptase; AQP 9—aquaporin 9; MYBL1—v-myb myeloblastosis viral oncogene homolog (avian)-like 1; STAB1—stabilin 1; ASGR2—asialoglycoprotein receptor 2.
doi:10.1371/journal.pone.0050054.g002
or 4th quartile of the study group with the controls, the major results were the same (data not shown). Obviously the left ventricle ejection fraction was different – but this cannot be avoided. Other clinical factors were not significantly different.

Conclusions

ST-segment elevation myocardial infarction alters expression of several groups of genes. On admission, several genes and pathways that could be directly or indirectly linked with lipid/glucose metabolism, platelet function and atherosclerotic plaque stability were affected (signaling of PPAR, IL-10, IL-6). Analysis at discharge highlighted specific immune response (upregulation of immunoglobulins). Highly significant and substantial upregulation of SOCS3 and FAM20 genes expression in the first 4–6 days of myocardial infarction in all patients is the most robust observation of our work.

Supporting Information

Table S1 Primers sequences and reaction conditions used for Real-time PCR.

(DOC)

References

1. Barron HV, Haer SD, Radford MJ, Wang Y, Krumholz HM (2001) The association between white blood cell count and acute myocardial infarction mortality in patients 26–5 years of age: findings from the cooperative cardiovascular project. J Am Coll Cardiol 38: 1654–1661.
2. Mueller C, Neumann FJ, Pernschoud AP, Buettner HJ (2003) White blood cell count and long term mortality after non-ST elevation acute coronary syndrome treated with very early revascularisation. Heart 89: 389–392.
3. Ndrepepa G, Braun S, Iijima R, Keta D, Byrne RA, et al. (2009) Total leukocyte count, but not C-reactive protein, predicts 1-year mortality in patients with acute coronary syndromes treated with percutaneous coronary intervention. Clin Sci (Lond) 116: 651–658.
4. Libby P, Ridker PM, Hansson GK (2011) Progress and challenges in translating the biology of atherosclerosis. Nature 473: 317–325.
5. Van de Werf F, Bax J, Betriu A, Bloemstrom-Lundqvist C, Crea F, et al. (2008) Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation. The Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology. European Heart Journal 29: 2909–2945.
6. Pfaffl MW (2001) A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Research 29: e45.
7. Pfaffl MW, Morgan GW, Dimpfel W (2002) Relative expression software tool (REST) for group-wise comparison and statistical analysis of relative expression results in real-time PCR. Nucleic Acids Research 30: e36.
8. Holley CL, Topkara VK (2011) An Introduction to Small Non-coding RNAs: miRNA and snoRNA. Cardiovasc Drugs Ther 25: 151–159.
9. Tamiyi T, Kashiwagi I, Takahashi R, Yasukawa H, Yoshimura A (2011) Suppressors of Cytokine Signaling (SOCS) Proteins and JAK/STAT Pathways: Regulation of T-Cell Inflammation by SOCS1 and SOCS3. Arterioscler Thromb Vasc Biol 31: 980–985.
10. Gupta GK, Dhar K, Del Core MG, Hunter WJ 3rd, Hatzoudis GI, et al. (2011) Aquaglyceroporin AQP9: solute permeation and metabolic control of immune regulation. Nat Rev Immunol 7: 454–465.

Table S2 Annotated genes with expression at admission significantly different from 6 months after MI.

(DOC)

Table S3 Annotated genes with expression at admission significantly different from control.

(DOC)

Table S4 Annotated genes with expression at discharge significantly different from 6 months after MI.

(DOC)

Table S5 Annotated genes with expression at discharge significantly different from control.

(DOC)

Author Contributions

Conceived and designed the experiments: MK BB MG GO. Performed the experiments: MK MM AW EG JK. Analyzed the data: MK BB MG GO. Contributed reagents/materials/analysis tools: BB MG AM AL. Wrote the paper: MK BB. Critical review of the manuscript: JK GO.

Table S2 Annotated genes with expression at admission significantly different from 6 months after MI.

(DOC)

Table S3 Annotated genes with expression at admission significantly different from control.

(DOC)

Table S4 Annotated genes with expression at discharge significantly different from 6 months after MI.

(DOC)

Table S5 Annotated genes with expression at discharge significantly different from control.

(DOC)
35. Ait-Oufella H, Taleb S, Mallat Z, Tedgui A (2011) Recent advances on the role of cytokines in atherosclerosis. Arterioscler Thromb Vasc Biol 31: 969–979.

36. Potteaux S, Esposito B, van Oostrom O, Brun V, Ardonin P, et al. (2004) Leukocyte-derived interleukin 10 is required for protection against atherosclerosis in low-density lipoprotein receptor knockout mice. Arterioscler Thromb Vasc Biol 24: 1474–1478.

37. Cavusoglu E, Marmur JD, Hojjati MR, Chopra V, Butala M, et al. (2011) Plasma interleukin-10 levels and adverse outcomes in acute coronary syndrome. Am J Med 128: 724–730.

38. Calkin AC, Tontonoz P (2010) Liver X Receptor Signaling Pathways and Atherosclerosis. Arterioscler Thromb Vasc Biol 30: 1513–1518.